MedTrace Logo

Interest of Peticate Syneo Infant Formula in Children Allergic to Cow's Milk Protein: Real Life Study

NCT04893330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2023-09-22

No results posted yet for this study

Summary

Nutricia wants to launch a real-life study, to see how the presence of prebiotics and probiotics in the boosted protein hydrolyzate can improve symptoms in the first weeks of use, and supplement the efficacy and safety data of the drug. formula, collected during clinical trials, with real life use. The target population will be children with a definite or suspected diagnosis of APLV, who have never taken a hypoallergenic formula, for whom the doctor decides to prescribe the Pepsicate Syneo formula, regardless of the clinical manifestation of the allergy. These children will be included before the age of 8 months and will be seen again 4 weeks after the prescription. The data from this real-life study will also better characterize the profile of infants taking Pepsicate Syneo. Finally, the perception of the formula by the parents will be collected.

Conditions

  • Milk Hypersensitivity

Interventions

DIETARY_SUPPLEMENT

pepticate syneo

follow up of pepticate syneo for one month

Sponsors & Collaborators

  • Nutricia Nutrition Clinique

    lead INDUSTRY

Eligibility

Min Age
8 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893330 on ClinicalTrials.gov